HUP0304045A2 - Use of ikb-kinase inhibitors for treating of inflammatory and immune diseases and pharmaceutical compositions containing them - Google Patents
Use of ikb-kinase inhibitors for treating of inflammatory and immune diseases and pharmaceutical compositions containing themInfo
- Publication number
- HUP0304045A2 HUP0304045A2 HU0304045A HUP0304045A HUP0304045A2 HU P0304045 A2 HUP0304045 A2 HU P0304045A2 HU 0304045 A HU0304045 A HU 0304045A HU P0304045 A HUP0304045 A HU P0304045A HU P0304045 A2 HUP0304045 A2 HU P0304045A2
- Authority
- HU
- Hungary
- Prior art keywords
- ikb
- inflammatory
- treating
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
- 208000026278 immune system disease Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26585301P | 2001-02-01 | 2001-02-01 | |
| US09/965,977 US6960585B2 (en) | 2000-10-03 | 2001-09-27 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
| PCT/US2002/003060 WO2002060386A2 (en) | 2001-02-01 | 2002-02-01 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0304045A2 true HUP0304045A2 (en) | 2004-04-28 |
| HUP0304045A3 HUP0304045A3 (en) | 2005-05-30 |
Family
ID=26951465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0304045A HUP0304045A3 (en) | 2001-02-01 | 2002-02-01 | Use of ikb-kinase inhibitors for treating of inflammatory and immune diseases and pharmaceutical compositions containing them |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1363993A4 (en) |
| JP (1) | JP2004529088A (en) |
| AU (1) | AU2002247059B2 (en) |
| CA (1) | CA2436770A1 (en) |
| CZ (1) | CZ20032287A3 (en) |
| HU (1) | HUP0304045A3 (en) |
| MX (1) | MXPA03006817A (en) |
| NO (1) | NO20033429L (en) |
| PL (1) | PL364111A1 (en) |
| WO (1) | WO2002060386A2 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002028860A2 (en) * | 2000-10-03 | 2002-04-11 | Bristol-Myers Squibb Company | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
| AU2002239806B2 (en) | 2000-10-26 | 2007-01-18 | Amgen Inc. | Antiinflammation agents |
| AR037641A1 (en) | 2001-12-05 | 2004-11-17 | Tularik Inc | INFLAMMATION MODULATORS |
| DE10237722A1 (en) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indole or benzimidazole derivatives for the modulation of IKappaB kinase |
| CA2502429A1 (en) | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
| TW200616967A (en) | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
| TW200626142A (en) | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| JP5059756B2 (en) | 2005-06-30 | 2012-10-31 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Compound |
| EA200800755A1 (en) * | 2005-09-07 | 2008-10-30 | Лаборатуар Сероно С.А. | IKK INHIBITORS INTRODUCED FOR THE TREATMENT OF ENDOMETRIOSIS |
| US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| US8299080B2 (en) * | 2006-12-13 | 2012-10-30 | Aska Pharmaceutical Co., Ltd. | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor |
| AR065804A1 (en) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT |
| MX2010011545A (en) | 2008-04-21 | 2011-04-11 | Otonomy Inc | Auris formulations for treating otic diseases and conditions. |
| WO2010000903A2 (en) * | 2008-06-30 | 2010-01-07 | Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas (Ciemat) | Composition capable of modulating ikkalpha activity for the treatment of diseases associated with acantholysis |
| AU2009298981B2 (en) | 2008-10-02 | 2012-09-27 | Asahi Kasei Pharma Corporation | 8-substituted isoquinoline derivative and use thereof |
| WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| AU2017290256A1 (en) | 2016-06-29 | 2019-01-17 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
| EP3494994A1 (en) * | 2017-12-07 | 2019-06-12 | Universität zu Köln | Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4160097A (en) * | 1977-01-07 | 1979-07-03 | Westwind Pharmaceuticals, Inc. | 1-(2-Phenylureylene)imidazoles |
| US5851812A (en) * | 1997-07-01 | 1998-12-22 | Tularik Inc. | IKK-β proteins, nucleic acids and methods |
| US6235740B1 (en) * | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
| US6030834A (en) * | 1997-12-30 | 2000-02-29 | Chiron Corporation | Human IKK-beta DNA constructs and cells |
| GB0003154D0 (en) * | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| MXPA02007981A (en) * | 2000-03-15 | 2004-04-05 | Aventis Pharma Gmbh | Substituted beta carbolines with ikb kinase inhibiting activity. |
| WO2002028860A2 (en) * | 2000-10-03 | 2002-04-11 | Bristol-Myers Squibb Company | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
-
2002
- 2002-02-01 WO PCT/US2002/003060 patent/WO2002060386A2/en active Application Filing
- 2002-02-01 MX MXPA03006817A patent/MXPA03006817A/en active IP Right Grant
- 2002-02-01 HU HU0304045A patent/HUP0304045A3/en unknown
- 2002-02-01 EP EP02714815A patent/EP1363993A4/en not_active Withdrawn
- 2002-02-01 JP JP2002560582A patent/JP2004529088A/en active Pending
- 2002-02-01 CZ CZ20032287A patent/CZ20032287A3/en unknown
- 2002-02-01 CA CA002436770A patent/CA2436770A1/en not_active Abandoned
- 2002-02-01 AU AU2002247059A patent/AU2002247059B2/en not_active Ceased
- 2002-02-01 PL PL02364111A patent/PL364111A1/en not_active Application Discontinuation
-
2003
- 2003-07-31 NO NO20033429A patent/NO20033429L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL364111A1 (en) | 2004-12-13 |
| AU2002247059B2 (en) | 2006-11-16 |
| NO20033429L (en) | 2003-09-24 |
| WO2002060386A2 (en) | 2002-08-08 |
| EP1363993A4 (en) | 2008-11-12 |
| NO20033429D0 (en) | 2003-07-31 |
| EP1363993A2 (en) | 2003-11-26 |
| MXPA03006817A (en) | 2003-11-13 |
| CA2436770A1 (en) | 2002-08-08 |
| WO2002060386A3 (en) | 2002-10-10 |
| JP2004529088A (en) | 2004-09-24 |
| HUP0304045A3 (en) | 2005-05-30 |
| CZ20032287A3 (en) | 2004-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0304045A3 (en) | Use of ikb-kinase inhibitors for treating of inflammatory and immune diseases and pharmaceutical compositions containing them | |
| EP1575480A4 (en) | Compositions and methods for the treatment of immune related diseases | |
| EP1578367A4 (en) | Compositions and methods for the treatment of immune related diseases | |
| EP1572116A4 (en) | Compositions and methods for the treatment of immune related diseases | |
| EP1576137A4 (en) | Compositions and methods for the treatment of immune related diseases | |
| TWI346558B (en) | Pharmaceutical composition for chronic treatment of inflammation and use thereof | |
| HUP0401711A3 (en) | N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them | |
| HUP0201463A3 (en) | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect and their use | |
| EP1443905A4 (en) | Compositions for oral gene therapy and methods of using same | |
| HK1091840A1 (en) | Methods and compositions for therapeutic use of rna interference | |
| IL166108A0 (en) | Novel compounds pharmaceutical compositions containing same and methods of use for same | |
| HUP0400918A3 (en) | Utilization of pyrazoline derivatives in the preparation of pharmaceutical compositions for the prevention and/or treatment of proliferative cell diseases | |
| EP1560593A4 (en) | Novel composition and methods for the treatment of immune related diseases | |
| EP1379242A4 (en) | Method for treatment of cancer and compositions for use therein | |
| HUP0201846A2 (en) | Amonobenzophenones as inhibitors of il-1betha and tnf-alpha and pharmaceutical compositions containing them | |
| HUP0200613A2 (en) | Compounds and methods for treatment of asthma, allergy and inflammatory disorders, pharmaceutical compositions containing them and their use | |
| HUP0401392A3 (en) | Use of composition comprising anti-hla-antibody for treatment of diseases involving prolierative immune response | |
| IL166054A0 (en) | Novel compounds pharmaceutical compositions containing same and methods of use for same | |
| EP1691820A4 (en) | Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use | |
| EP1578373A4 (en) | Novel compositions and methods for the treatment of immune related diseases | |
| EP1416795A4 (en) | Compositions and methods for treatment of mitochondrial diseases | |
| IL156506A0 (en) | Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof | |
| HUP0300402A3 (en) | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them | |
| IL155174A0 (en) | Methods and compositions for the treatment of inflammatory diseases | |
| EP1472273A4 (en) | Compositions and methods for the treatment of immune related diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |